EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Tzogani, Kyriaki, Penttilä, Karri, Lähteenvuo, Johanna, Lapveteläinen, Tuomo, Lopez Anglada, Lucía, Prieto, Carolina, Garcia‐Ochoa, Blanca, Enzmann, Harald, Gisselbrecht, Christian, Delgado, Julio, Pignatti, Francesco
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2020
Aiheet:
Regulatory Issues: EMA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794172/
https://ncbi.nlm.nih.gov/pubmed/33179377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13592
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia